报价延迟最少15分钟:2025/09/03 18:55 EDT
盘后时段
|
||||
|
12.54 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.87
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.88/-3.38
|
|
企业价值
25.40M
|
| 资产负债 |
|
每股账面净值
2.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/03 18:55 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. |
